The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater.

Aim: To evaluate the role of intravitreal ranubizumab (IVR) in the treatment of familial exudative vitreoretinopathy (FEVR) of stage 2 or greater either as primary or an ajunct to conventional treatments.

Methods: Retrospective, non-controlled clinical study. Thirty patients (37 eyes) diagnosed with FEVR were enrolled.